Claritas Pharmaceuticals, Inc. engages in the development of next generation cannabinoid therapeutics. The company is headquartered in San Rafael California, California. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The firm has leased a laboratory, office, and archival space in Beverly, Massachusetts.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue
0
0
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
1
1
3
3
3
3
Research & Development
--
-2
5
7
1
1
Operating Expenses
0
-12
-7
4
4
5
Other Non Operating Income (Expenses)
-2
0
0
-2
-17
0
Pretax Income
-1
0
-25
6
-31
-11
Income Tax Expense
0
-4
-4
0
0
0
Net Income
-4
4
-21
6
-31
-11
Net Income Growth
33%
-119%
-450%
-119%
182%
--
Shares Outstanding (Diluted)
35.41
26.69
22.44
10.91
6.2
1.47
Shares Change (YoY)
31%
19%
106%
76%
322%
1,251%
EPS (Diluted)
-0.13
0.16
-0.95
0.64
-5.13
-7.86
EPS Growth
0%
-117%
-248%
-112%
-35%
773%
Free Cash Flow
0
0
-6
-4
-5
-1
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
--
--
--
--
--
--
EBITDA Margin
--
--
--
--
--
--
D&A For EBITDA
--
--
--
--
--
--
EBIT
0
12
7
-4
-4
-5
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
0%
0%
16%
0%
0%
0%
Follow-Up Questions
What are Claritas Pharmaceuticals, Inc.'s key financial statements?
According to the latest financial statement (Form-10K), Claritas Pharmaceuticals, Inc. has a total asset of $10, Net profit of $4
What are the key financial ratios for CLAZF?
Claritas Pharmaceuticals, Inc.'s Current ratio is 1.25, has a Net margin is 0, sales per share of $0.
How is Claritas Pharmaceuticals, Inc.'s revenue broken down by segment or geography?
Claritas Pharmaceuticals, Inc. largest revenue segment is Gaming and Application Services, at a revenue of 4,628,836,511 in the most earnings release.For geography, China is the primary market for Claritas Pharmaceuticals, Inc., at a revenue of 3,888,487,868.
Is Claritas Pharmaceuticals, Inc. profitable?
yes, according to the latest financial statements, Claritas Pharmaceuticals, Inc. has a net profit of $4
Does Claritas Pharmaceuticals, Inc. have any liabilities?
yes, Claritas Pharmaceuticals, Inc. has liability of 8
How many outstanding shares for Claritas Pharmaceuticals, Inc.?
Claritas Pharmaceuticals, Inc. has a total outstanding shares of 27.3